CY1115528T1 - Ολοκληρα βακτηριακα κυτταρα ως ανοσολογικοι ρυθμιστες - Google Patents

Ολοκληρα βακτηριακα κυτταρα ως ανοσολογικοι ρυθμιστες

Info

Publication number
CY1115528T1
CY1115528T1 CY20141100417T CY141100417T CY1115528T1 CY 1115528 T1 CY1115528 T1 CY 1115528T1 CY 20141100417 T CY20141100417 T CY 20141100417T CY 141100417 T CY141100417 T CY 141100417T CY 1115528 T1 CY1115528 T1 CY 1115528T1
Authority
CY
Cyprus
Prior art keywords
bacterial cells
immune regulators
regulators
immune
composition
Prior art date
Application number
CY20141100417T
Other languages
English (en)
Inventor
Graham Mcintyre
John Lawson Stanford
Cynthia Ann Stanford
Oscar Adelmo Bottasso
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220809A external-priority patent/GB0220809D0/en
Priority claimed from GB0317144A external-priority patent/GB0317144D0/en
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of CY1115528T1 publication Critical patent/CY1115528T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Μία σύνθεση και/ή μία φαρμακευτική σύνθεση ανοσολογικού ρυθμιστή, η οποία περιλαμβάνει ένα ολόκληρο κύτταρο βακτηρίου από τα είδη Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella και Nocardioides, στην οποία η αναφερθείσα σύνθεση ανοσολογικού ρυθμιστή ρυθμίζει μία κυτταρική ανοσολογική απόκριση.
CY20141100417T 2002-09-06 2014-06-11 Ολοκληρα βακτηριακα κυτταρα ως ανοσολογικοι ρυθμιστες CY1115528T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0220809A GB0220809D0 (en) 2002-09-06 2002-09-06 Immune modulator
GB0317144A GB0317144D0 (en) 2003-07-22 2003-07-22 Immune modulator
EP03793906.3A EP1534330B8 (en) 2002-09-06 2003-09-05 Whole bacterial cells as immune modulator

Publications (1)

Publication Number Publication Date
CY1115528T1 true CY1115528T1 (el) 2017-01-04

Family

ID=31980021

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100417T CY1115528T1 (el) 2002-09-06 2014-06-11 Ολοκληρα βακτηριακα κυτταρα ως ανοσολογικοι ρυθμιστες

Country Status (12)

Country Link
US (1) US7579009B2 (el)
EP (1) EP1534330B8 (el)
JP (1) JP5101795B2 (el)
AR (1) AR041171A1 (el)
AU (1) AU2003263319B2 (el)
CA (1) CA2497644C (el)
CY (1) CY1115528T1 (el)
DK (1) DK1534330T3 (el)
ES (1) ES2471241T3 (el)
PT (1) PT1534330E (el)
SI (1) SI1534330T1 (el)
WO (1) WO2004022093A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413728B2 (en) 2003-11-14 2008-08-19 Ucl Biomedica Plc Immune modulator
AU2004203226B2 (en) * 2004-07-19 2010-07-08 Ucl Biomedica Plc Vaccine
US7442374B2 (en) 2004-07-19 2008-10-28 Ucl Biomedica Plc Composition for increasing the survival to slaughter rate of piglets
CN1935262B (zh) * 2005-09-23 2010-12-29 沈阳胜宝康生物制药有限公司 红色诺卡氏菌细胞壁骨架在制备抗人乳头瘤病毒药物的用途
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method
GB0526031D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Use
JP2008156295A (ja) * 2006-12-25 2008-07-10 Japan Energy Corp 皮膚外用剤
EP2170082A4 (en) * 2007-06-29 2012-01-11 Commw Scient Ind Res Org PROCESS FOR REMOVING TOXIC COMPOUNDS
GB0716778D0 (en) 2007-08-29 2007-10-10 Bioeos Ltd Use
WO2010002847A1 (en) 2008-06-30 2010-01-07 Randal Haworth Jaw thrust device and method
EP2399595B1 (en) * 2009-02-20 2015-11-04 Meisho.Co., Ltd Immunopotentiating composition and process for producing same
WO2013012875A2 (en) 2011-07-18 2013-01-24 Mount Sinai School Of Medicine Bacterial rnas as vaccine adjuvants
AU2017222692A1 (en) * 2016-02-25 2018-09-27 Thomas Julius Borody Compositions and methods of treatment of chronic infectious diseases
CN109576180B (zh) * 2018-12-17 2021-11-26 北京利昂盛生物技术有限公司 一株赤红球菌及其作为免疫佐剂在制备疫苗中的应用
KR20210114436A (ko) * 2019-01-15 2021-09-23 랴오닝 그레이티스트 바이오-파마슈티컬 컴퍼니 리미티드 로도코커스 루버로부터 유래하는 생성물 및 이의 약학 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599310A (en) * 1984-06-18 1986-07-08 Bristol-Myers Company Process for producing antitumor antibiotic compound
US5759992A (en) * 1994-08-31 1998-06-02 David Platt Immunotherapeutic agent derived from bacteria and method for its manufacture
ATE402413T1 (de) * 1997-03-03 2008-08-15 Adcock Ingram Ltd Eine zusammensetzung, die eine trägerkomponente und eine gereinigte mykobakterielle zellwandkomponente enthält, und ihre verwendung zur verhinderung, behandlung und diagnose von erkrankungen
CA2298558A1 (en) 1997-07-28 1999-02-04 Temple University - Of The Commonwealth System Of Higher Education Genetically engineered rhodococcus vaccine
GB0025694D0 (en) * 2000-10-19 2000-12-06 Univ London Vaccine
NZ555055A (en) * 2001-12-11 2010-06-25 Pasteur Institut Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
WO2003101399A2 (en) 2002-06-03 2003-12-11 Click Robert E Novel bacterium for treatment of disease
GB0526032D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Use

Also Published As

Publication number Publication date
JP2006503022A (ja) 2006-01-26
JP5101795B2 (ja) 2012-12-19
EP1534330B1 (en) 2014-03-12
DK1534330T3 (da) 2014-06-16
SI1534330T1 (sl) 2014-08-29
US7579009B2 (en) 2009-08-25
AU2003263319B2 (en) 2009-07-02
ES2471241T3 (es) 2014-06-25
EP1534330A1 (en) 2005-06-01
CA2497644A1 (en) 2004-03-18
WO2004022093A1 (en) 2004-03-18
PT1534330E (pt) 2014-06-23
CA2497644C (en) 2014-08-12
US20060134136A1 (en) 2006-06-22
AU2003263319A1 (en) 2004-03-29
EP1534330B8 (en) 2014-06-04
AR041171A1 (es) 2005-05-04

Similar Documents

Publication Publication Date Title
CY1115528T1 (el) Ολοκληρα βακτηριακα κυτταρα ως ανοσολογικοι ρυθμιστες
DE69635419D1 (de) Alkalophile und thermophile mikroorganismen und damit erhaltene enzymen
ATE530669T1 (de) Markierte mikroorganismen und entsprechende markierungsverfahren
ATE454463T1 (de) Überexpression von extremozymgenen in pseudomonas und nahe verwandte bakterien
WO2004058159A3 (en) Branched immunomodulatory compounds and methods of using the same
MX2007007288A (es) Desacilacion de lps en bacterias gram negativas.
WO2004100624A3 (en) Lighting methods and systems
BR9713391A (pt) Métodos e composições de detoxificação de zearalenona
DE60210623D1 (de) Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen
EP1539819A4 (en) METHOD AND COMPOSITIONS FOR CREATING AND CONTROLLING THE EFFECTOR PROFILE OF T-CELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUB-GROUPS OF ANTIGEN-PRESENTING CELLS
ATE283067T1 (de) Detoxifizierte mutanten bakterieller adp- ribosylierender toxine als parenterale adjuvantien
DK0807178T3 (da) Mycobaktielle proteiner, mikroorganismer producerende samme og anvendelser af nævnte proteiner i vacciner og til påvisning af tuberkulose
BRPI0620291B8 (pt) método e uso de 4,4'-diaminodifenil sulfona para produzir cepas rugosas de bactérias e composição de modulador imune
ATE261491T1 (de) Nachweis von mikroorganismen
WO2005107047A3 (en) Functionalized electroactive polymers
GB0607956D0 (en) Immune modulator comprising whole cell rhodococcus gordonia, nocardia, dietzia, tsukamurella or nocardioides bacteria
ATE544471T1 (de) Zusammensetzung mit iscom-teilchen und lebenden mikroorganismen
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
DE60222250D1 (de) Zellulares kunststoffmaterial
DK0863981T3 (da) Detektering, forebyggelse og behandling af papillomatous digital dermatitis
IT1317849B1 (it) Mezzi e metodi per l'espressione di proteine omologhe ed eterologhe inceppi di rhodococcus.
BR0016616A (pt) Microrganismos atenuados para o tratamento de infecção
DE502004005902D1 (de) Dämpferlager
ATE412014T1 (de) Immunmodulatorische konstrukte und deren verwendungen
DK2030625T3 (da) Anvendelse af actinomyceter til behandling af type II-diabetes